Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

CNS therapeutic delivery is a multi-layered hierarchy rather than just crossing the blood-brain barrier. Effective delivery requires achieving adequate exposure in specific anatomical brain regions, verifying target engagement within precise cell types, and achieving proper intracellular trafficking for advanced modalities like ASOs, siRNAs, and AAVs.

Related Insights

Recognizing that severe myotonic dystrophy involves CNS impairment, Arthex deliberately invested in a lipid conjugation delivery system for its RNA therapeutic. This strategic choice was made specifically to cross the blood-brain barrier, enabling the treatment of both muscular and neurological symptoms of the disease.

The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.

Advanced cell therapy isn't just about replacing lost cells. Transplanted, genetically engineered cells can be programmed to produce and secrete therapeutics locally. This turns them into a delivery platform that solves the critical challenge of the blood-brain barrier for large molecules.

The historical difficulty of delivering biologics to the brain is being addressed by novel "brain shuttle" technologies. These platforms, which facilitate transport across the blood-brain barrier, are enabling new enzyme replacement therapies and even AAV-delivered biologics for CNS diseases like leukodystrophies.

The biotech industry often oversimplifies the challenge of genetic medicine as a 'delivery' problem. In reality, it's three distinct but interconnected issues—potency, specificity, and delivery—masquerading as one. Solving it requires a complex, multi-faceted solution, not a single silver bullet, which is why progress has been slow.

The success of the IDH inhibitor vorasidenib in glioma was driven by its specific design for blood-brain barrier (BBB) penetration. This contrasts with its predecessor, which failed in brain tumors due to poor CNS penetration, highlighting that BBB is a critical design consideration for neuro-oncology drugs.

Voyager CEO Al Sandrock explains their AAV capsids are engineered to be so potent at crossing the blood-brain barrier that doses can be an order of magnitude lower than standard. Crucially, the capsids are also designed to *avoid* the liver, directly addressing the toxicity issues that have plagued the field.

Voyager's ALPL-based blood-brain barrier shuttle offers a different pharmacokinetic profile than transferrin receptor shuttles. While delivering a lower initial peak concentration (Cmax), it provides a much longer half-life. This steady, sustained exposure is optimal for therapies that require constant pathway blockage, highlighting a key strategic trade-off in delivery system design.

nChroma develops distinct epigenetic silencing platforms (CRISPR-OFF and CHARM). The smaller CHARM platform can be delivered via AAVs, opening up CNS targets inaccessible to the larger CRISPR-OFF platform, which uses LNPs for liver targets. This tailored approach expands their therapeutic reach.

Bio Arctic is strategically expanding its brain transporter platform beyond its initial focus. It's now being applied to new modalities like enzymes, ASOs, and siRNAs, and is venturing outside of neurology into oncology through a partnership for glioblastoma. This demonstrates the technology's broad applicability.